Dr. Reddy's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Rs. 8 per equity share.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's reported strong FY25 results with consolidated revenue of Rs. 32,554 crore (up 17% YoY) and Q4 revenue of Rs. 8,506 crore (up 20% YoY), aided by the acquired NRT business from Haleon. Q4 EBITDA margin expanded to 29.1% from 26.4% a year ago, while Q4 PAT attributable to shareholders rose 22% YoY to Rs. 1,594 crore. FY25 PAT grew modestly at 2% YoY to Rs. 5,654 crore due to higher costs and impairments of Rs. 169 crore on product intangibles. The Board recommended a final dividend of Rs. 8 per share (face value Rs. 1) for FY25, with record date fixed at July 10, 2025. Statutory auditors issued an unqualified/unmodified opinion on the financial statements. G V Prasad was re-appointed as Co-Chairman & MD for 5 years effective January 2026.
Positive for shareholders — strong Q4 performance with 20% revenue growth, expanding EBITDA margins, and a confirmed dividend payout signal healthy cash generation. Continued investment in R&D and recent acquisitions (Haleon NRT, Nestle nutraceuticals JV) support future growth, though gross margin pressure and ongoing FCPA investigation in the US remain watchpoints.